175 related articles for article (PubMed ID: 36502529)
21. Theoretical Investigations on Interactions of Arylsulphonyl Indazole Derivatives as Potential Ligands of VEGFR2 Kinase.
Czaja K; Kujawski J; Śliwa P; Kurczab R; Kujawski R; Stodolna A; Myślińska A; Bernard MK
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32645858
[TBL] [Abstract][Full Text] [Related]
22. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors.
Hoi PM; Li S; Vong CT; Tseng HH; Kwan YW; Lee SM
Methods; 2015 Jan; 71():85-91. PubMed ID: 25239735
[TBL] [Abstract][Full Text] [Related]
24. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
Zhu J; Wu Y; Xu L; Jin J
Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
[TBL] [Abstract][Full Text] [Related]
25. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.
Rampogu S; Baek A; Zeb A; Lee KW
BMC Cancer; 2018 Mar; 18(1):264. PubMed ID: 29514608
[TBL] [Abstract][Full Text] [Related]
26. Discovery of potential FGFR3 inhibitors via QSAR, pharmacophore modeling, virtual screening and molecular docking studies against bladder cancer.
Ganji M; Bakhshi S; Shoari A; Ahangari Cohan R
J Transl Med; 2023 Feb; 21(1):111. PubMed ID: 36765337
[TBL] [Abstract][Full Text] [Related]
27. Reveal the interaction mechanism of five old drugs targeting VEGFR2 through computational simulations.
Lv Y; Wang Y; Zheng X; Liang G
J Mol Graph Model; 2020 May; 96():107538. PubMed ID: 31981898
[TBL] [Abstract][Full Text] [Related]
28. Identification of Phytochemicals Targeting c-Met Kinase Domain using Consensus Docking and Molecular Dynamics Simulation Studies.
Aliebrahimi S; Montasser Kouhsari S; Ostad SN; Arab SS; Karami L
Cell Biochem Biophys; 2018 Jun; 76(1-2):135-145. PubMed ID: 28852971
[TBL] [Abstract][Full Text] [Related]
29. Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations.
Ma S; Zeng G; Fang D; Wang J; Wu W; Xie W; Tan S; Zheng K
Mol Biosyst; 2015 Feb; 11(2):394-406. PubMed ID: 25406390
[TBL] [Abstract][Full Text] [Related]
30. Identification of novel discoidin domain receptor 1 (DDR1) inhibitors using E-pharmacophore modeling, structure-based virtual screening, molecular dynamics simulation and MM-GBSA approaches.
Nada H; Lee K; Gotina L; Pae AN; Elkamhawy A
Comput Biol Med; 2022 Mar; 142():105217. PubMed ID: 35032738
[TBL] [Abstract][Full Text] [Related]
31. Computational prediction of small molecules with predicted binding to FGFR3 and testing biological effects in bone cells.
Mohan S; Muthusamy K; Nagamani S; Kesavan C
Exp Biol Med (Maywood); 2021 Jul; 246(14):1660-1667. PubMed ID: 33779341
[TBL] [Abstract][Full Text] [Related]
32. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
Gao C; Grøtli M; Eriksson LA
J Mol Model; 2015 Jul; 21(7):167. PubMed ID: 26044359
[TBL] [Abstract][Full Text] [Related]
33. Substrate-specific conformational regulation of the receptor tyrosine kinase VEGFR2 catalytic domain.
Solowiej J; Chen JH; Zou HY; Grant SK; Murray BW
ACS Chem Biol; 2013 May; 8(5):978-86. PubMed ID: 23441851
[TBL] [Abstract][Full Text] [Related]
34. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
[TBL] [Abstract][Full Text] [Related]
35. Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations.
Muñoz C; Adasme F; Alzate-Morales JH; Vergara-Jaque A; Kniess T; Caballero J
J Mol Graph Model; 2012 Feb; 32():39-48. PubMed ID: 22070999
[TBL] [Abstract][Full Text] [Related]
36. Structure-based pharmacophore modeling, virtual screening and simulation studies for the identification of potent anticancerous phytochemical lead targeting cyclin-dependent kinase 2.
Sharma M; Sharma N; Muddassir M; Rahman QI; Dwivedi UN; Akhtar S
J Biomol Struct Dyn; 2022; 40(20):9815-9832. PubMed ID: 34151738
[TBL] [Abstract][Full Text] [Related]
37. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel potential β-N-acetyl-D-hexosaminidase inhibitors by virtual screening, molecular dynamics simulation and MM-PBSA calculations.
Liu J; Liu M; Yao Y; Wang J; Li Y; Li G; Wang Y
Int J Mol Sci; 2012; 13(4):4545-4563. PubMed ID: 22605995
[TBL] [Abstract][Full Text] [Related]
39. Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, 'DFG-out' inhibitors.
Modi SJ; Kulkarni VM
J Biomol Struct Dyn; 2022 Aug; 40(12):5712-5727. PubMed ID: 33459187
[TBL] [Abstract][Full Text] [Related]
40. A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex--medicinal chemistry consequences of a TKs analysis.
Lintnerová L; García-Caballero M; Gregáň F; Melicherčík M; Quesada AR; Dobiaš J; Lác J; Sališová M; Boháč A
Eur J Med Chem; 2014 Jan; 72():146-59. PubMed ID: 24368209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
